Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment
Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment
New labeling clears the way for the treatment of many more patients.
January 10, 2012, Neuchâtel, Switzerland – Pulmonx SARL today announced that its European notified body has granted CE approval for expanded labeling of its Zephyr® endobronchial valve (EBV). The approval was based upon an…
Pulmonx Reports New Publication Confirms Efficacy of Emphysema Treatment
Zephyr® Endobronchial Valve (EBV) therapy guided by Chartis®Assessment is effective in a broad range of patients.
May 10, 2012 ,Peseux, Switzerland, Pulmonx, an emerging leader in interventional pulmonology, announced today that the European Respiratory Journal has published the results of the…
Pulmonx to Market Zephyr® EBV Therapy for Patients with “Genetic” Emphysema
Company Receives Approval to Revise CE Labeling
August 29, 2012, Peseux, Switzerland – Pulmonx, an emerging leader in interventional pulmonology, announced today that its European notified body has granted CE approval for revised labeling of its Zephyr® Endobronchial Valve (EBV). The approval was…
Pulmonx Gets FDA Nod for U.S. Trial of Emphysema Therapy
IDE for Study of Zephyr® Endobronchial Valve Approved
August 27, 2012, Redwood City, CA, USA – Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to…
Pulmonx to Market Zephyr® EBV Therapy for Patients with “Genetic” Emphysema
August 29, 2012, Peseux, Switzerland – Pulmonx, an emerging leader in interventional pulmonology, announced today that its European notified body has granted CE approval for revised labeling of its Zephyr® Endobronchial Valve (EBV).
Pulmonx Gets FDA Nod for U.S. Trial of Emphysema Therapy
August 27, 2012, Redwood City, CA, USA – Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to commence a multi-center pivotal clinical trial.
Pulmonx Reports New Publication Confirms Efficacy of Emphysema Treatment
May 10, 2012 ,Peseux, Switzerland, Pulmonx, an emerging leader in interventional pulmonology, announced today that the European Respiratory Journal has published the results of the Chartis®Multi-Centre study.
Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment
January 10, 2012, Neuchâtel, Switzerland – Pulmonx SARL today announced that its European notified body has granted CE approval for expanded labeling of its Zephyr® endobronchial valve (EBV). The approval was based upon an independent review of clinical data from numerous studies including the recently completed Chartis multi-center study1 and the European VENT study (a randomized multi-center European trial of Zephyr EBV therapy)2.